174 related articles for article (PubMed ID: 34312289)
1. Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c-PCK2 Axis in Basal-Like Breast Cancer.
Chao CH; Wang CY; Wang CH; Chen TW; Hsu HY; Huang HW; Li CW; Mai RT
Mol Cancer Res; 2021 Nov; 19(11):1900-1916. PubMed ID: 34312289
[TBL] [Abstract][Full Text] [Related]
2. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.
Chang CJ; Chao CH; Xia W; Yang JY; Xiong Y; Li CW; Yu WH; Rehman SK; Hsu JL; Lee HH; Liu M; Chen CT; Yu D; Hung MC
Nat Cell Biol; 2011 Mar; 13(3):317-23. PubMed ID: 21336307
[TBL] [Abstract][Full Text] [Related]
3. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium.
Feng ZM; Qiu J; Chen XW; Liao RX; Liao XY; Zhang LP; Chen X; Li Y; Chen ZT; Sun JG
BMC Cancer; 2015 Sep; 15():645. PubMed ID: 26400441
[TBL] [Abstract][Full Text] [Related]
4. Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53-miR34a axis.
Avtanski DB; Nagalingam A; Tomaszewski JE; Risbood P; Difillippantonio MJ; Saxena NK; Malhotra SV; Sharma D
Mol Oncol; 2016 Aug; 10(7):1118-32. PubMed ID: 27259808
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53-microRNA-200c-ZEB2-Axis-Induced CPT1C Elevation Contributes to Metabolic Reprogramming and Tumor Progression in Basal-Like Breast Cancers.
Wang CY; Wang CH; Mai RT; Chen TW; Li CW; Chao CH
Front Oncol; 2022; 12():940402. PubMed ID: 35936710
[No Abstract] [Full Text] [Related]
6. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.
Ren D; Wang M; Guo W; Zhao X; Tu X; Huang S; Zou X; Peng X
Int J Oncol; 2013 Apr; 42(4):1473-81. PubMed ID: 23404342
[TBL] [Abstract][Full Text] [Related]
7. miR-34a and miR-200c Have an Additive Tumor-Suppressive Effect on Breast Cancer Cells and Patient Prognosis.
Mansoori B; Silvestris N; Mohammadi A; Khaze V; Baghbani E; Mokhtarzadeh A; Shanehbandi D; Derakhshani A; Duijf PHG; Baradaran B
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33673143
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness.
Ghatak D; Datta A; Roychowdhury T; Chattopadhyay S; Roychoudhury S
Mol Cancer Res; 2021 Oct; 19(10):1635-1650. PubMed ID: 34257080
[TBL] [Abstract][Full Text] [Related]
9. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential.
Knezevic J; Pfefferle AD; Petrovic I; Greene SB; Perou CM; Rosen JM
Oncogene; 2015 Dec; 34(49):5997-6006. PubMed ID: 25746005
[TBL] [Abstract][Full Text] [Related]
10. Bioluminescence Imaging for Monitoring miR-200c Expression in Breast Cancer Cells and its Effects on Epithelial-Mesenchymal Transition Progress in Living Animals.
Liu J; Shen JX; He D; Zhang GJ
Mol Imaging Biol; 2018 Oct; 20(5):761-770. PubMed ID: 29532351
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
12. miR-200c/141 Regulates Breast Cancer Stem Cell Heterogeneity via Targeting HIPK1/β-Catenin Axis.
Liu B; Du R; Zhou L; Xu J; Chen S; Chen J; Yang X; Liu DX; Shao ZM; Zhang L; Yu Z; Xie N; Guan JL; Liu S
Theranostics; 2018; 8(21):5801-5813. PubMed ID: 30613263
[TBL] [Abstract][Full Text] [Related]
13. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
14. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-200c overexpression plays an inhibitory role in human pancreatic cancer stem cells by regulating epithelial-mesenchymal transition.
Ma C; Ding YC; Yu W; Wang Q; Meng B; Huang T
Minerva Med; 2015 Aug; 106(4):193-202. PubMed ID: 26081037
[TBL] [Abstract][Full Text] [Related]
16. The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
Raza U; Saatci Ö; Uhlmann S; Ansari SA; Eyüpoğlu E; Yurdusev E; Mutlu M; Ersan PG; Altundağ MK; Zhang JD; Doğan HT; Güler G; Şahin Ö
Oncotarget; 2016 Aug; 7(31):49859-49877. PubMed ID: 27409664
[TBL] [Abstract][Full Text] [Related]
17. miR-200c-3p Regulates Epitelial-to-Mesenchymal Transition in Epicardial Mesothelial Cells by Targeting Epicardial Follistatin-Related Protein 1.
Pontemezzo E; Foglio E; Vernucci E; Magenta A; D'Agostino M; Sileno S; Astanina E; Bussolino F; Pellegrini L; Germani A; Russo MA; Limana F
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067060
[TBL] [Abstract][Full Text] [Related]
18. Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
Ye J; Wei X; Shang Y; Pan Q; Yang M; Tian Y; He Y; Peng Z; Chen L; Chen W; Wang R
Oncogene; 2017 Nov; 36(46):6391-6407. PubMed ID: 28745318
[TBL] [Abstract][Full Text] [Related]
19. Targets of miR-200c mediate suppression of cell motility and anoikis resistance.
Howe EN; Cochrane DR; Richer JK
Breast Cancer Res; 2011 Apr; 13(2):R45. PubMed ID: 21501518
[TBL] [Abstract][Full Text] [Related]
20. p53 Spreads out further: suppression of EMT and stemness by activating miR-200c expression.
Schubert J; Brabletz T
Cell Res; 2011 May; 21(5):705-7. PubMed ID: 21483453
[No Abstract] [Full Text] [Related]
[Next] [New Search]
